Role of Stem Cell Transplant in MDS

EP: 1.Diagnosing Lower-Risk MDS

EP: 2.Classifying MDS: Updated WHO and ICC Guidelines

EP: 3.Risk Stratification Tools for MDS: IPSS, IPSS-R, IPSS-M

EP: 4.Importance of Early Detection and Unmet Needs in MDS

EP: 5.Lower-Risk MDS: Treatment Goals and Options

EP: 6.Choosing Treatment for Lower-Risk MDS

Now Viewing

EP: 7.Role of Stem Cell Transplant in MDS

EP: 8.MEDALIST: Clinical Implications in Lower-Risk MDS

EP: 9.Imetelstat and Canakinumab in Lower-Risk MDS

This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD.

Drs Safah and Koprivnikar outline eligibility criteria for allogeneic stem cell transplant referral in myelodysplastic syndrome (MDS), still relying predominantly on Revised International Prognostic Scoring System (IPSS-R) risk stratification. Candidates are typically higher risk, now defined as intermediate-2 or high by IPSS-R. Debate remains regarding very high-risk disease.

Equally important is assessing patient fitness, not just age, via the hematopoietic cell transplantation–specific comorbidity index given the elder MDS population. The goal is to select those most likely to benefit and tolerate intense therapy to achieve potential cure rather than undue toxicity.

Exceptions may include lower-risk MDS with very heavy transfusion dependence or adverse molecular features unresponsive to other treatments. Careful patient selection allows optimal application of this potentially curative modality only available to appropriately fit candidates.

Ongoing reevaluation of evolving criteria should further enhance appropriate utilization moving forward.

Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.